What is the recommended starting dose, titration, baseline investigations, monitoring schedule, and safety precautions for initiating lithium therapy in an adult with bipolar disorder, assuming no severe renal impairment, uncontrolled thyroid disease, or prior lithium toxicity?

Lithium Initiation Protocol for Bipolar Disorder

Starting Dose and Titration

Begin lithium at 300 mg three times daily (900 mg/day total) for adults weighing ≥30 kg, or 300 mg twice daily (600 mg/day) for those <30 kg, with weekly dose increases of 300 mg until therapeutic levels of 0.8–1.2 mEq/L are achieved for acute treatment. 1, 2

• Target serum concentration for acute mania is 0.8–1.2 mEq/L, while maintenance therapy requires 0.6–1.0 mEq/L 1, 3
• Some patients respond at lower concentrations, but therapeutic monitoring guides optimization 1
• Measure lithium levels twice weekly during the acute phase until both laboratory values and clinical symptoms stabilize 1, 3
• After stabilization, check lithium levels every 3–6 months during maintenance therapy 1, 2

Baseline Investigations (Before First Dose)

Obtain a comprehensive metabolic and organ-function panel before initiating lithium to establish safety and reference values for future monitoring. 1, 2

Required baseline tests:

• Complete blood count (CBC) 1, 2
• Thyroid function tests: TSH and free T4 1, 2
• Renal function: blood urea nitrogen (BUN), serum creatinine, urinalysis 1, 2
• Serum calcium 1, 2
• Pregnancy test in all individuals of childbearing potential 1, 2
• Baseline body mass index and blood pressure 1

Monitoring Schedule

Acute Phase (First 4–8 Weeks)

• Lithium level: twice weekly until stable 1, 3
• Clinical assessment: weekly for mood symptoms, adverse effects, and medication adherence 1

Maintenance Phase (After Stabilization)

• Lithium level: every 3–6 months 1, 2, 3
• Renal function (BUN, creatinine): every 3–6 months 1, 2
• Thyroid function (TSH): every 3–6 months 1, 2
• Urinalysis: every 3–6 months 1, 2
• Clinical assessment: monthly initially, then quarterly once stable 1

Critical Safety Precautions

Lithium has a narrow therapeutic window and carries significant overdose risk, requiring strict safety measures and patient education. 1, 4

Toxicity Prevention

• Educate patients on early signs of lithium toxicity: fine tremor, nausea, diarrhea 1
• Instruct patients to seek immediate medical attention if coarse tremor, confusion, or ataxia develop 1
• Maintain adequate hydration and consistent salt intake, as dehydration and sodium depletion increase lithium levels 3
• Avoid NSAIDs, ACE inhibitors, and thiazide diuretics, which can elevate lithium levels 3

Overdose Risk Management

• Lithium overdoses can be lethal; prescribe limited quantities (7–14 day supplies) with frequent refills in patients with suicidal history 1
• Implement third-party medication supervision for patients with active suicidal ideation or prior overdose attempts 1
• Engage family members to secure lithium and remove access to lethal quantities 1

Discontinuation Precautions

• Never discontinue lithium abruptly—taper gradually over 2–4 weeks minimum (10–20% dose reduction every 1–2 weeks) to prevent rebound mania 1
• Withdrawal of lithium dramatically increases relapse risk, with >90% of noncompliant patients relapsing versus 37.5% of compliant patients 1, 2
• Relapse risk is highest within 6 months of discontinuation 1, 2

Duration of Treatment

Continue lithium maintenance therapy for at least 12–24 months after achieving mood stabilization; many patients require lifelong treatment. 1, 2

• Premature discontinuation leads to high relapse rates 1, 2
• Patients with multiple severe episodes, rapid cycling, or poor response to alternatives should be counseled that indefinite treatment may be necessary 1

Unique Advantages of Lithium

Lithium is the only mood stabilizer proven to reduce suicide attempts by 8.6-fold and completed suicides by 9-fold, an effect independent of its mood-stabilizing properties. 1, 5

• This anti-suicidal effect is thought to stem from central serotonin enhancement, reduction of aggression/impulsivity, and modulation of stress responses 1
• Lithium is the only drug effective in prophylaxis of manic, depressive, and suicidal symptoms 4, 6, 5
• In non-enriched trials, lithium prevents both manic and depressive episodes more effectively than other mood stabilizers 1, 6

Common Pitfalls to Avoid

• Underdosing: Failing to achieve therapeutic levels (0.8–1.2 mEq/L for acute treatment) delays response 1, 3
• Inadequate trial duration: Lithium requires 4–6 weeks at therapeutic levels before concluding ineffectiveness 1
• Insufficient monitoring: Missing scheduled renal and thyroid function tests can allow serious adverse effects to develop undetected 1, 2
• Rapid discontinuation: Abrupt cessation precipitates rebound mania in the majority of patients 1
• Ignoring drug interactions: NSAIDs, ACE inhibitors, and diuretics can precipitate toxicity 3